Calton & Associates’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Calton & Associates’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-12,589	Closed	-$695K	–	297
2019 Q1	$695K	Buy	12,589 +5,690	+82%	+$301K	0.21%	93
2018 Q4	$325K	Buy	+6,899	New	+$355K	0.12%	159
2018 Q1	–	Sell	-544	Closed	-$28K	–	995
2017 Q4	$28K	Buy	+544	New	+$25.5K	0.01%	820

Other funds holding PBE

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Calton & Associates's PBE Position: Q2 2019 in Review

Calton & Associates sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2019, closing a stake of 12,589 shares — an estimated $695K sold.

Calton & Associates first reported a position in PBE in Q4 2017 and held it in 3 quarters. The position peaked at $695K in Q1 2019. 81 funds tracked by Wall St. Rank hold PBE as of Q2 2019.

Calton & Associates reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2019 after selling out during the quarter.
Calton & Associates sold 12,589 Invesco Biotechnology & Genome ETF shares in Q2 2019, an estimated $695K.
Calton & Associates first reported a position in Invesco Biotechnology & Genome ETF in Q4 2017 and held it in 3 quarters.
Calton & Associates's Invesco Biotechnology & Genome ETF position peaked at $695K in Q1 2019.
81 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2019.

Based on Calton & Associates's 13F filing for Q2 2019, filed 9 Jul 2019.